Non-albuminuric chronic kidney disease in diabetes: A different approach?
作者信息
Borg Rikke, Persson Frederik
机构信息
Department of Nephrology, Zealand University Hospital, 4000 Roskilde; Department of Clinical Medicine, University of Copenhagen, 1017 Copenhagen, Denmark.
Steno Diabetes Center Copenhagen, 2730 Herlev, Denmark.
出版信息
Indian J Med Res. 2022 Oct-Nov;156(4&5):685-686. doi: 10.4103/ijmr.ijmr_1018_22.
Abstract
摘要
相似文献
1
Non-albuminuric chronic kidney disease in diabetes: A different approach?糖尿病中的非白蛋白尿性慢性肾脏病：一种不同的方法？
Indian J Med Res. 2022 Oct-Nov;156(4&5):685-686. doi: 10.4103/ijmr.ijmr_1018_22.
2
Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality.1 型糖尿病患者的白蛋白尿和非白蛋白尿性慢性肾脏病：与主要血管结局风险和全因死亡率的关联。
J Diabetes Complications. 2018 Jun;32(6):550-557. doi: 10.1016/j.jdiacomp.2018.03.012. Epub 2018 Apr 3.
3
Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre.在中国一家糖尿病中心，2型糖尿病合并肾脏疾病患者中微血管和大血管并发症的患病率，无论有无蛋白尿。
Diab Vasc Dis Res. 2016 Jan;13(1):21-30. doi: 10.1177/1479164115610247. Epub 2015 Oct 23.
4
Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes.高血压和2型糖尿病患者的肾脏疾病指标与肾功能恶化风险的关联
J Diabetes Complications. 2017 Feb;31(2):419-426. doi: 10.1016/j.jdiacomp.2016.10.030. Epub 2016 Oct 29.
5
Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes.白蛋白尿的变化可作为糖尿病患者心血管和肾脏结局的替代终点。
Diabetes Obes Metab. 2023 Jun;25(6):1434-1443. doi: 10.1111/dom.15030. Epub 2023 Mar 8.
6
Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency.2型糖尿病合并非白蛋白尿性肾机能不全患者的肾脏转归及全因死亡率
Diabetologia. 2022 Jan;65(1):234-245. doi: 10.1007/s00125-021-05590-5. Epub 2021 Nov 5.
7
Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus.2型糖尿病相关慢性肾衰竭晚期患者中的非白蛋白尿性肾病
Ren Fail. 2014 Mar;36(2):166-70. doi: 10.3109/0886022X.2013.835266. Epub 2013 Sep 24.
8
Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study.白蛋白尿型慢性肾脏病与 2 型糖尿病患者糖尿病视网膜病变的真实世界关联：来自 No blind 研究的结果。
Nutr Metab Cardiovasc Dis. 2019 Sep;29(9):923-930. doi: 10.1016/j.numecd.2019.05.065. Epub 2019 Jun 7.
9
Risk of Rapid Kidney Function Decline, All-Cause Mortality, and Major Cardiovascular Events in Nonalbuminuric Chronic Kidney Disease in Type 2 Diabetes.2型糖尿病非白蛋白尿性慢性肾脏病患者肾功能快速下降、全因死亡率及主要心血管事件的风险
Diabetes Care. 2020 Jan;43(1):122-129. doi: 10.2337/dc19-1438. Epub 2019 Dec 3.
10
Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study.非白蛋白尿性肾功能不全是 2 型糖尿病患者死亡的强有力预测因素：肾功能不全和心血管事件（RIACE）意大利多中心研究。
Diabetologia. 2018 Nov;61(11):2277-2289. doi: 10.1007/s00125-018-4691-2. Epub 2018 Jul 21.
本文引用的文献
1
Prevalence of normoalbuminuric chronic kidney disease among individuals with type 2 diabetes mellitus from India.印度 2 型糖尿病患者正常白蛋白尿期慢性肾脏病的患病率。
Indian J Med Res. 2022 Oct-Nov;156(4&5):632-639. doi: 10.4103/ijmr.IJMR_2595_19.
2
Empagliflozin in Patients with Chronic Kidney Disease.恩格列净在慢性肾脏病患者中的应用。
N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4.
3
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.9. 血糖治疗的药物学方法：《2022 年糖尿病医学诊疗标准》。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009.
4
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.在肾脏病和 2 型糖尿病患者中用非奈利酮发生的心血管事件。
N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28.
5
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.非奈利酮对 2 型糖尿病患者慢性肾脏病结局的影响。
N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23.
6
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
7
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.
8
Diagnosis of diabetic kidney disease: state of the art and future perspective.糖尿病肾病的诊断：现状与未来展望
Kidney Int Suppl (2011). 2018 Jan;8(1):2-7. doi: 10.1016/j.kisu.2017.10.003. Epub 2017 Dec 29.
9
Microalbuminuria: a parameter that has changed diabetes care.微量白蛋白尿：一个改变糖尿病治疗的参数。
Diabetes Res Clin Pract. 2015 Jan;107(1):1-8. doi: 10.1016/j.diabres.2014.10.014. Epub 2014 Oct 24.
10
Combined angiotensin inhibition for the treatment of diabetic nephropathy.联合应用血管紧张素抑制剂治疗糖尿病肾病。
N Engl J Med. 2013 Nov 14;369(20):1892-903. doi: 10.1056/NEJMoa1303154. Epub 2013 Nov 9.
Zotero 插件